LAKE (38) NTRB (40) AGPU (37) APT (58) ⌘ Pro Terminal →

Conexeu Sciences Inc. (CNXU) — RQD Stock Rating Cockpit

$2.83 -1.74% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.82

Conexeu Sciences Inc. (CNXU) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $85.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.82 (-0.50%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY • 51.8% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE-1.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CNXU)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (56/100 Composite)

🔍 WHY CNXU SCORES 56/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 33.9 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$3.89-21.3% Next Q

Q2 (-2Q)

Grade C$3.06+1.3% Next Q

Q3 (-1Q)

Grade C$3.10-8.7% Next Q

Current

Grade D+$2.83-0.4% Hist 90D α

Trajectory: C+ (64) → D+ (56)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CNXU Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 56/100 (D+) score, CNXU faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($4.41) or 200D SMA ($7.93) invalidates the momentum regime and cuts Target Base ($2.80) toward Bear Floor ($2.18).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CNXU• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CNXU Beats Next Quarter EPS Consensus (Jan 29, 2027) & Holds Above 200D SMA”

YES 56%NO 44%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

33.930 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $2$2.83H: $19

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 10 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 18 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B-RQD 28 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on CNXU

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (50)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (55)

18/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like CNXU

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CNXU)

✓Walkthrough of CNXU's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CNXU // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -78.35%⚡ TESTING RESISTANCE

2026-10-30O $2.85H $2.85L $2.43C $2.83VOL 517.3K

RES: $3.09SUP: $0.81SMA50: $4.41SMA200: $7.93

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CNXU Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CNXU Butterfly Map → + Track CNXU →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CNXU today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CNXU. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CNXU today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CNXU)

Health Care Rank #269 of 1016 ⚔️ LAKE vs CNXU Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CNXU vs. LAKE, NTRB, AGPU, APT)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Conexeu Sciences Inc. (CNXU) ranks #269 by composite RQD confidence (56/100, grade D+) and #680 by equity capitalization ($85.8M). Within this direct 5-issuer industry benchmark cohort, APT leads on earnings valuation at 16.2x trailing P/E, while APT leads on capital efficiency and profitability with 6.7% ROIC and 38.1% gross margin. APT currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with CNXU at 56/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CNXU ACTIVE Conexeu Sciences Inc.	D+	56/100	—	—	—	-1.74%	$85.8M	Benchmark Subject
LAKE Lakeland Industries Inc.	D-	38/100	—	32.9%	-9.5%	-1.11%	$88.2M	/lake-vs-cnxu →
NTRB Nutriband Inc.	D-	40/100	—	27.8%	-35.0%	+3.75%	$80.7M	/ntrb-vs-cnxu →
AGPU Axe Compute Inc.	D-	37/100	—	—	-35.0%	-2.01%	$101.7M	/agpu-vs-cnxu →
APT Alpha Pro Tech Ltd.	D+	58/100	16.2x	38.1%	6.7%	+1.28%	$56.6M	/apt-vs-cnxu →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-10-31 • CIK 0002066836

In its most recent audited fiscal period (FY2025, filed 2025-10-31), Conexeu Sciences Inc. (CNXU) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, CNXU closed FY2025 with $7.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-10-31	$0	$0	—	—	$7.7M	—

3. CNXU Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CNXU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Conexeu Sciences Inc. (NASDAQ: CNXU) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $2.83 (-1.74% 1D, market cap $85.8M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, CNXU ranks #269 in composite RQD confidence.

How does CNXU compare to LAKE and NTRB in the Health Care sector?

Within the Health Care sector (Industrial Specialties), CNXU carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, LAKE (Lakeland Industries Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -9.5%, cap $88.2M) and NTRB (Nutriband Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $80.7M). Among the 5-stock peer group, APT leads on earnings multiple (16.2x) while APT leads on capital efficiency (6.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CNXU?

Per CNXU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-10-31, CIK 0002066836), Conexeu Sciences Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $7.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CNXU trading relative to its 50-day, 200-day, and 52-week technical levels?

CNXU last traded at $2.83 (-1.74% on volume of 413,953 shares), positioning the stock -35.83% below its 50-day simple moving average ($4.41) and -64.31% below its 200-day simple moving average ($7.93). Across its 52-week range of $2.43 to $18.79, CNXU sits at the 2.4% percentile with a 14-day RSI of 33.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.48 to $3.18).

CNXU Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell CNXU stock right now?

Conexeu Sciences Inc. (CNXU) currently earns a Roarable Rating of D+ (Sell — SELL) with 56/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is CNXU's 12-month price target and RQD AI Jury consensus?

CNXU's 12-month base price target is $2.8 (range $2.18 to $19.73), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: CNXU RQD Cockpit CNXU 12M Forecast CNXU Earnings & Move CNXU Dividends & DRIP CNXU Insiders & 13F CNXU Whale Options CNXU Profit Sankey CNXU News & Why